Once-Weekly Hypofractionated Radiotherapy for Breast Cancer in Elderly Patients : Efficacy and Tolerance in 486 Patients by Sanz, Javier et al.
Clinical Study
Once-Weekly Hypofractionated Radiotherapy for Breast Cancer
in Elderly Patients: Efficacy and Tolerance in 486 Patients
Javier Sanz ,1,2 Min Zhao,3 Nuria Rodríguez,1,2 Raquel Granado ,1 Palmira Foro ,1,2
Ana Reig ,1 Ismael Membrive ,1 andManuel Algara 1,2
1Radiation Oncology Department, Hospital del Mar, Parc de Salut Mar, Barcelona, Spain
2Pompeu Fabra University, Barcelona, Spain
3Autonomous University of Barcelona, Barcelona, Spain
Correspondence should be addressed to Javier Sanz; jsanz@parcdesalutmar.cat
Received 25 August 2017; Revised 20 November 2017; Accepted 31 December 2017; Published 15 March 2018
Academic Editor: Pierfrancesco Franco
Copyright © 2018 Javier Sanz et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Purpose. Radiation therapy is a key treatment of breast cancer. Elderly patients with associated diseases that modify their
performance status do not tolerate long periods of daily irradiation. The objective of this study is to analyze the results of weekly
hypofractionated treatment in these patients. Material and Methods. Between 1992 and 2016, we included 486 elderly patients
presenting concomitant pathology or sociofamilial problems in which it was not feasible to propose conventional treatment. They
were treated with conservative surgery or mastectomy and then adjuvant hypofractionated irradiation, administering 5Gy or
6.25Gy in 6 fractions, once a week (total dose 30–37.5Gy) over 6 weeks. Results. Breast cancer overall survival according to the
Kaplan-Meier method at 5 years was 74.2% ± 2.3%; breast cancer disease-free survival was 90% ± 1.6%; local relapse-free survival
was 96.5% ± 1% showing that patients die more from other causes and not from their neoplasia. Acute dermatitis was mild (75.6%
of the patients grades I–III) and 30.6% hadmoderate chronic fibrosis.Conclusions.The once-weekly hypofractionated radiotherapy
is a feasible and convenient option for elderly patients with breast cancer. It is a safe treatment modality with similar survival and
local control results compared to standard fractionation, while the side effects are acceptable.
1. Introduction
Breast cancer is the most common tumor in women [1].
The incidence rate continues to increase slowly in both
developed and underdeveloped countries. It is the leading
cause of cancer mortality in women. Survival of breast
cancer has really improved in the last 20 years, approximately
1.4% annually [2], mainly due to the early detection of this
neoplasm, improvements in surgical techniques, systemic
treatments, and radiotherapy.
The treatment of breast neoplasia combines surgery,
systemic treatment, and radiotherapy. The most common
regimen for the complementary treatment of breast cancer
after conservative [3] or radical surgery has been the standard
fractionation, consisting of 45–50Gy in 25 fractions of 1.8
or 2Gy/day, 5 days a week, for 33 days [4, 5]. These studies
show that the incidence of local recurrence is significantly
lower in the group of patients treated with radiotherapy,
about an 8%–10% with respect to the nonirradiated ones in
which the local recurrence reached 25%–35%, independently
of other associated factors. One of the most important risk
factors for the development of breast cancer is age [6].
Most cases are diagnosed between the ages of 35 and 80,
nearly half of them diagnosed at the age of 70 or more
years [7]. Currently, approximately 30% of patients in a
radiotherapy department have breast cancer [8]. Elderly
patients are frequently associated with concomitant diseases,
cognitive impairment, sociofamilial problems, or functional
limitation [9]. Patients often live far from the hospital and
have difficulty to attend the radiotherapy sessions. Therefore,
according to established practice, it is not always feasible for
elderly patients to indicate a conventional, daily treatment
[10]. This may lead to individuals avoiding complementary
treatment after conservative surgery, or unnecessary abuse of
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radical mastectomy in the initial stages, which results in an
undertreatment or overtreatment in a large number of cases.
Therefore, it is advisable to plan a more convenient treatment
regimen for the elderly patients while a similar local control
result can be achieved.
Today, although the current standard is moderate daily
hypofractionation, there are still many patients who cannot
tolerate it and require a more adapted treatment to their
condition. There are other fractionation schedules that can
shorten the radiation treatment, demonstrating the same
efficacy, without increasing complications. Aside improve-
ment in quality of life [11], also short treatments can relieve
the pressure of medical resources and logistical problems of
access to the radiotherapy.One of the current challenges is the
definition of irradiation schedules that are more comfortable
for patients and easier to integrate with systemic therapies. In
any case, there is no clear consensus on what should be used
on a regular basis [12, 13].
The purpose of the present observational study is to
analyze the results of weekly hypofractionated irradiation
treatment in older patients with breast cancer in terms
of survival, locoregional control, tolerance, and acute and
chronic toxicity.
2. Materials and Methods
2.1. Patient Selection. Elderly patients with nonmetastatic
breast neoplasia treated between 1992 and 2016 have been
included. Inclusion criteria have been patients older than
70 years and/or those patients who do not tolerate daily
travel to our radiotherapy department for several reasons
such as those associated with concomitant diseases, cognitive
impairment (according to the global deterioration scale or
GDS of 4 or higher), sociofamilial problems, functional
limitation, or living away from the treatment center. The
criteria for the choice of initial surgery were the same as
those used for young patients. So patients with I-II stages
underwent conservative treatment and lymphadenectomy
(or sentinel node selective biopsy), and patients with stage
III were submitted to radical treatment with mastectomy and
lymphadenectomy. In patients with conservative surgery, the
marginswere considered positive if the tumor reached the ink
of the sample or close when they were negative but inferior to
3mm.The characteristics of the patients are shown in Table 1.
2.2. Treatment. They received weekly hypofractionated irra-
diation within 2 months after surgery. The patients were
treated with a cobalt unit or a linear accelerator by means
3D conformal tangential beams to the breast volume or
field in field modulated techniques to optimize dosimetric
distribution. All patients were treated in supine position,
with abduction of ipsilateral arm utilizing an alpha-cradle
immobilization.
The radiation schedule consisted of 6.25Gy per fraction
once aweek but in the recent part of the series the fractionwas
reduced to 5Gywith the aimof reducing the risk of secondary
effects. Patients treated with conservative surgery or only
biopsy received irradiation to the breast and mastectomized
patients to the chest wall. In patients with T4 tumors treated
Table 1: Characteristics of the patients.
n %
Stage
I 187 38.5
II 182 37.4
III 80 16.5
IV 5 1
In situ 11 2.26
Recurrence 10 2
Unknown 11 2.3
Histologic grade
1 85 17.5
2 218 44.8
3 100 20.5
Unknown 83 17
Surgical type
Brest-conserving surgery 382 78.6
Mastectomy 97 20
with electrons to the chest wall a bolus was utilized. Patients
with positive surgical margin were considered to receive
radiotherapy to the tumor bed by adding 1 or 2 additional
weekly doses at this level. The boost volume consisted in the
tumor bedmarkedwith clips and additionalmargin of 15mm
in all directions to obtain the PTV. The supraclavicular fossa
was irradiated as a function of the nodal involvement, always
in N2 cases and in patients with N1 involvement treated in
the period from 2008 to 2016 according to our guideline
and evidence published data [14]. In these cases, additional
anterior and posterior fields to supraclavicular fossa and
lymph node level III were utilized.
2.3. Evaluation and Follow-Up. All patients were evaluated
weekly after the session for tolerance and underwent control
of acute and chronic local toxicity according to the RTOG
scale or the Common Terminology Criteria for Adverse
Events v4.0 (CTCAE), indicating supportive treatment when
necessary. Patients were followed periodically after the end
of treatment, at a month, 6 months, and subsequently at least
once a year.
Patients were included following the ethical principles for
medical research according to Helsinki declaration and an
informed consent was obtained from all the patients.
2.4. Statistical Analysis. The statistical analysis was per-
formed with SPSS v22 (IBM SPSS, Chicago, IL). Chi-square
and exact Fisher tests were employed to evaluate categorical
variables. The actuarial rates of overall survival, disease-
free survival, local relapse-free survival, and metastasis-
free survival were calculated according to the Kaplan-Meier
method and comparisons were made using the log-rank test.
3. Results
3.1. Patients and Treatment Characteristics. Four hundred
and eighty-six patients have been included. The median
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age of patients was 79 ± 6.5 years (range 58–97). Half of
the patients lived outside Barcelona, which makes it more
difficult for them to get to the hospital. Breast conservative
surgery was performed in 78.6% (73.3% tumorectomy and
5.3% quadrantectomy) and total mastectomy in 20% and only
biopsy in 0.6% were performed by associated pathology that
contraindicated the intervention or occasionally because of
the refusal of the patient to be operated on. Patients without
chemotherapy were treated postoperatively at 2.2 months
(range: 1–3 months), and patients with adjuvant chemother-
apy were treated 4.5 months (range: 2.5–4.6 months) after
surgery. Hormonal therapy was utilized in 78.7% of the cases;
among them 57.8%were treated with aromatase inhibitors. In
13.4% of the patients neoadjuvant or adjuvant chemotherapy
was administered, mainly anthracyclines, taxanes, or CMF
schedules.
Patients were treated in 13.4% of cases using 1.25MV
photons of a Cobalt-60 unit or by means of a linear
accelerator unit so that 69.3% of the cases were treated
with 6MV photons (337 patients), and 17.3% of the cases
corresponding to mastectomized patients were treated with
electrons (84 patients). 80.7% of cases received a total of
6 sessions. 90.7% of patients received a fractionation of
6.25Gy/fraction and 9.3% (45 patients) at 5Gy/fraction up
to a total dose of 30Gy. An amount of 17.5% of patients with
positive surgical margin after conservative surgery received
a boost to the tumor bed of 1 or 2 additional doses (7.2%
and 10.3% of patients, resp.). None of the patients treated
with mastectomy received a boost. In 15% of the series, the
patients received irradiation to the supraclavicular fosa and
axillar level III cause of positivity of lymph nodes in the
lymphadenectomy. Only 9 patients (1.8%) did not complete
the treatment (1 patient received 4 sessions and 8 patients
received 5 sessions) mainly due to complications of their
comorbidities.
3.2. Recurrence and Survival. Local control was excellent,
reaching 96.5% ± 1% at 5 years, and only 16 patients had local
recurrence. After a median follow-up of 51 months (range:
1–163 months), the status of the patients was as follows: 341
(70%) were disease-free, 45 (9.3%) died as a result of cancer
progression, and 95 (19.5%) died of another disease.Mortality
was more frequently caused by concomitant diseases than by
neoplasia.
So, overall survival according to the Kaplan-Meier
method at 5 years was 74.2% ± 2.3%; breast cancer specific
survival was 90% ± 1.6%; relapse-free survival was 96.5% ±
1%; metastasis-free survival was 90% ± 1.6% (Figure 1).
Estimated survival at 5 years according to the disease stage
is presented in Figure 2: Patients with grade 1-2 histology
had better survival rates than those of grade 3 (𝑝 = 0.002).
Survival according to the histologic grade at 5 years is shown
in Figure 2.
Survival according to the positivity of estrogen receptors
was also significant. So, patients who had positive estrogen
receptors have better survival than those whose receptors
were negative. Overall, survival according to progesterone
receptor is not statistically significant.
3.3. Treatment Tolerance and Toxicities. The acute toxicity is
presented in Figure 2. Among patients who have presented
dermatitis, half of them were grade 1. Usually, the cases of
acute dermatitis were resolved in 1-2 months with the appro-
priate topical moisturizing treatment for patients who have
presented dermatitis grades 1 and 2 and with sulphadiazin
cream for patients with grade 3. There were no differences in
skin toxicity according to the treatment unit or the techniques
utilized for irradiation (𝑝 = 0.092 and 𝑝 = 0.174 for
acute and chronic toxicity, resp.). When comparing acute
toxicity among the fraction utilized, patients with 5Gy per
session presented dermatitis grade 1 in 65%, grade 2 in 30%,
and grade 3 in 5%, and the patients treated with 6.25Gy
presented dermatitis grades 1, 2, or 3 in 47%, 32.6%, and
13.7%, respectively. In terms of chronic toxicity, 30.9% of
the patients presented skin impairment (Figure 3). Among
them, 88% presented fibrosis, 8.7% had hyperpigmentation
or telangiectasia, and 3.3% had edema or mastitis. Among
patients with fibrosis, only one patient was grade IV. The
reporting of symptoms related to breast fibrosis was very
unusual. Chronic toxicity was lower in patient treated with
5Gy per session compared to patients treated with 6.25Gy
per session schedule (22.9% and 31.4%, resp.;𝑝 = 0.34).There
were no cases of pulmonary or thoracic sequelae in terms of
pneumonitis or rib fracture.
4. Discussion
Complementary radiotherapy is classically indicated for
patients who have undergone conservative surgery for all
types of infiltrating tumors and many intraductal carcinoma
tumors. The volume to be treated includes the entire breast
with a total dose between 45 and 50Gy, at a daily dose of
1.8–2Gy as a classical or standard fractionation. The good
results obtained with the conservative treatment provoke
a new attempt to reduce the therapeutic aggressiveness, in
this case focused on the radiotherapy. Hypofractionation
programs are being developed in order to reduce the number
of sessions, so as to increase patients’ comfort, especially the
comfort of elderly patients.
There is abundant experience in the hypofractionated
treatment in patients with breast cancer (Table 2). Shelley et
al. [15] demonstrated in a phase II studywith 294 patients that
treatment based on 40Gy in 16 fractions of 2.5 Gy and in 22
days after a mean follow-up of 5.5 years achieved a relapse-
free survival of 96.5% which had no difference in acute or
chronic local toxicity. In 2010, Whelan demonstrated in his
study with more than 1200 patients receiving 50Gy in 25
fractions or 42.56Gy in 16 fractions, after a 10-year follow-up,
that there were no significant differences in local recurrence
(6.7% versus 6.2%) and good aesthetic results were achieved
(71.3% versus 69.8%, resp.). Acute toxicity of grade 3 or higher
was only present in 3% in each group [11]. In the START-
A trial, a regimen of 50Gy in 25 fractions over 5 weeks was
compared with 41.6Gy or 39Gy in 13 fractions over 5 weeks
[16]. In START-B trial, a regimen of 50Gy in 25 fractions
over 5 weeks was compared with 40Gy in 15 fractions over
3 weeks [17]. After approximately 10 years of follow-up, it
has been confirmed that moderately daily hypofractionated
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Figure 1: Overall and disease-free survival curves according to stage (a and b) and according to histologic grade (c and d).
irradiation is safe and effective for patients with early breast
cancer. These results support the use of 40Gy in 15 fractions
(3 weeks), which has already been adopted by most centers
as the standard therapy for women who require adjuvant
radiotherapy for early stage invasive breast cancer.
More recently, results of the UK IMPORT LOW trial have
been published. In this trial the patients were randomized
to receive whole breast irradiation at a dose of 40Gy in 15
fractions, 36Gy towhole breast and 40Gy to the partial breast
(reduced-dose group) or 40Gy to the partial breast only.This
trail has showed noninferiority of partial breast and reduced-
dose radiotherapy compared with the standard whole breast
hypofractionated irradiation [18]. Also the same research
group is investigating, in the HIGH IMPORT Trial, the
intensification of hypofractionated treatments by comparing
the whole breast irradiation of 40Gy plus a sequential boost
of 16Gy (control group) with two test arms: arm 1 consisting
in whole breast irradiation up to 36Gy, the index quadrant
up to 40Gy, and concomitant boost up to 48Gy in 15
fractions, or arm 2 with whole breast receiving 36Gy, the
index quadrant receiving 40Gy, and a concomitant boost up
to 53Gy, also in 15 fractions. The trial is under recruitment.
From the radiobiological point of view, the limits to avoid
increase in chronic toxicity seem to be about 3.2–3.3 Gy per
fraction as reported by Qi et al. [19].
Although the 3-week daily schedule is a significant
improvement compared to the traditional 5-6-week schedule,
the requirements of daily therapy continue to be problem in
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Figure 2: Acute toxicity and dermatitis grade according to RTOG criteria.
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Figure 3: Chronic toxicity (any type) and fibrosis grade rates according to CTCAE v4.0 criteria.
regions with limited oncology care resources and in some
cases the patients are excluded to receive appropriate postop-
erative treatment [20]. Favorable results from the randomized
trials of the hypofractionated schedules described above
have provided enough data to allow further investigation
towards still more concentrated hypofractionated schedules
with fewer sessions.
The first published clinical trial of once-weekly hypofrac-
tionated radiotherapy regimen was carried out in 1987 and
published by Rostom et al. [21]. It was a phase II trial that
applied a dose per session of 6.5 Gy/day, one session per week
to older patients. It demonstrated a good locoregional control
result and an acceptable cosmetic outcome. In 2006,Ortholan
et al. published a similar study that included 150 patients
undergoing both conservative and radical surgical treatment,
using the same weekly hypofractionation schedule, in which
a good clinical outcome was also demonstrated [22]. Other
similar published studies have also shown similar locore-
gional control rates, with a slightly higher but acceptable
chronic toxicity inmost series [23–25].More recentlyDragun
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Table 2: Moderate daily hypofractionation and weekly hypofractionation schedules in breast cancer.
(a) Daily hypofractionated schedules
Author n RDT schedule Commentary
Shelley et al., 2000 [15] 294 40Gy in 2.5 Gy/s, 22 days
Deutsch, 2002 [38] 47 Different schedules since50Gy in 2Gy to 36Gy in 3Gy 80–89 years old
Whelan et al., 2002 [39] 1234
Standard schedule 50Gy in 2Gy/s, 35 days,
versus
hypofraction 42.5Gy in 2.65Gy/s, 22 days
Yarnold et al., 2005 [37] 1410
50Gy in 2Gy/s, 39Gy in 3Gy/s,
or
42.9Gy in 3.3 Gy/s
Haviland et al., 2013 [28] 2236
START A: 50Gy in 2Gy/s versus 41.6Gy or
39Gy in 13 s
START B: 50Gy in 2Gy/s versus 40Gy in
15 s
(b) Weekly hypofractionated schedules
Author n RDT schedule Commentary
Rostom et al., 1987 [21] 84 6.5Gy × 6 s
Bates, 1988 [40] 411
3Gy × 12 s (3 s/week = 28 days)
versus
6Gy × 6 s (2 s/week = 18 days)
53 p biopsy, 13 p
lumpectomy, 18 p
mastectomy
Baillet et al., 1990 [41] 230
45Gy (1.8 Gy × 25 s in 33 days)
versus
23Gy (5.75Gy × 4 s in 17 days)
Maher et al., 1995 [23] 70 6.5Gy × 5 s + boost 6.5 Gy × 2 s Biopsy or cytology only
Ortholan et al., 2005 [22] 150 6.5Gy × 5 s; supra 5.5 Gy × 5 s; boost 6.5 Gy
× 1 or 2 s
108 p lumpectomy, 43 p
mastectomy
Courdi et al., 2006 [24] 115 6.5 × 5 s Median age 83 years, biopsyonly
Sanz et al., 2008 [7] 262 6.25Gy × 6 s (+6.25Gy × 2 s if positivemargin in conservative surgery)
22 p biopsy, 174 p
lumpectomy, 66 p
mastectomy
Dragun et al., 2011 [26] 42 6Gy × 5 s 69% lumpectomy31% chemotherapy
Yarnold, 2011 [25] 915 50Gy (2Gy × 25 s) versus 28.5 Gy (5.7 × 5 s)or 30Gy (6Gy × 5 s)
Rovea et al., 2015 [27] 298 30Gy (6Gy × 5 s) or 32.5 Gy (6.5Gy × 5 s)
Brunt et al., 2016 [35] 352 40Gy in 15 s in 3 weeks versus 27Gy in 5 s in1 week or 26Gy in 5 s in 1 week
Patients that require lymph
node irradiation are
excluded
RDT: radiation therapy; s: session; p: patient.
et al. have published a phase 2 study which included 42
patients who underwent conservative surgery and received
weekly hypofractionated irradiation at 6Gy/week in 5 weeks,
total dose at 30Gy, demonstrating the feasibility of the weekly
schedule. At the same time, it was cost effective and had low
acute toxicity rates, although further monitoring is required
to confirm long-term results with a possible reduction of
chronic toxicity according to dose reduction per fraction [26].
These results have been also confirmed in another series of
Rovea et al. where 291 patients received 30 or 32.5 Gy in
5 fractions, with mild chronic toxicity in terms of fibrosis,
edema, or hyperpigmentation and also achieving good or
excellent cosmetic result in 86.4% of cases [27].
A common criticism of these studies regards their lim-
ited applicability in that they include mainly lymph-node-
negative, postmenopausal patients with biologically favorable
early stage invasive disease [28]. In the present study, we
included 486 patients, the majority in early stage, who have
received 5Gy or 6.25Gy in 6 sessions with 1-2 additional
fractions if they have the positive surgical margin. Treatment
tolerance was assessed and considered satisfactory. Long-
term toxicity was greater. Such toxicity was acceptable taking
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into consideration the fact that it rarely seems to impact
patients’ quality of life, as most cases have been reported
as asymptomatic along the follow-up. The results regarding
specific survival and local control were similar to the standard
treatment and matched with the series already published,
stressing that the survival of these older patients is more
influenced by their own comorbidities than for the evolution
of breast cancer, leading to a specific survival of 90%at 5 years.
In addition, in our series, we have irradiated the supr-
aclavicular fossa (in 15% of the series) in those patients
with involvement of 4 or more axillary lymph nodes, in
patients with 1–3 involved nodes during the period from
2008 to 2016, those with insufficient lymphadenectomy (less
than 10–12 nodes), or those with macroscopically supra-
clavicular involvement. The regional treatment volume was
on the nodes of the supraclavicular fossa. Radio dermatitis
is the most common acute toxicity and leads to the most
discomfort for patients [29]. Signs and symptoms that are
derivate from breast irradiation are conditioned by various
factors, such as the volume to be treated, the irradiation
technique, and the energy of the fractionation, the total dose,
as well as previous and/or concomitant systemic treatments
and comorbidities of the patient [30]. Radio induced skin
toxicity has been extensively documented and investigated,
but in most cases there is no standardization in prevention
and care [31, 32]. The chronic effects of irradiation at the
cutaneous level include hyperpigmentation, telangiectasia,
subcutaneous fibrosis, edema, and local pain that may con-
tinue to occur in the subsequent and long-term follow-up
of irradiated patients [33]. In our series, although acute and
chronic toxicity was acceptable and seems not to compromise
quality of life in most cases, the percentage of patients with
fibrosis increased over time, which presented 30.7% at a
median follow-up of 51 months. Agrawal et al. compared the
standard schedule (2Gy × 25 s) with the weekly hypofraction
scheme in 5.7Gy × 5 s or 6Gy × 5 and after a 3-year follow-up
showed that 28.5Gy or 30Gy in 5 sessions are comparable to
50Gy in 25 sessions.The 28.5Gy schedule had a slightly lower
acute toxicity and a more discreet cosmetic impairment [34].
Subsequently, the FAST Forward trial that compares the
daily schedule in oneweekwith theUK standard schedule at 3
weeks after primary surgery for early breast cancer is ongoing.
With a moderate reduction of the dose, it seems that there
is relatively better tolerance and less acute toxicity. However,
longer follow-up is required [35].
We decided to apply the 5Gy scheme in 6 sessions instead
of the 6.25Gy × 6 schedule starting in August 2012, with the
intention of reducing chronic toxicity without compromising
the oncologic result. Therefore, we included 45 patients
(9.3%) in the present study in which we administered 5Gy
per fraction. No difference in survival has been shown.
Although not significant, a trend towards lower chronic
toxicity with 5Gy has been observed in comparison with the
6.25Gy schedule in 6 sessions, although further monitoring
is necessary to confirm this data. In addition, in the last
years there was a tendency to include the patients with worse
physical conditions or comorbidities in suchweekly schedule.
We are looking forward to obtain good clinical results and
lower toxicity with a longer follow-up.
We irradiated whole breast after conservative surgery, but
actually there is a consolidated experience in schedules in
which the partial irradiation of the breast in selected favorable
cases is considered to be a more comfortable alternative for
the patients. It is possible to administer a high enough dose
to the involved quadrant of the breast. The most frequent
schedules consist in 3.85Gy doses twice a day, ten fractions
in a week, although other schedules have been utilized. Also
the partial breast irradiation can be performed by a single
intraoperative session [36]. This treatment achieves similar
results in terms of toxicity and local control, constituting a
good option in low risk patients [37]. Also, actually there
are several studies ongoing investigating the omission of the
adjuvant irradiation in elderly good prognosis patients after
conservative surgery.
5. Conclusions
Weekly hypofractionated radiation therapy is a feasible and
convenient option for patients with advanced breast cancer
who do not tolerate a daily treatment. It is a safe treatment
modality with similar survival and local control results. The
side effects are also acceptable. As with the weekly hypofrac-
tionation schedule, the reduction of total time treatment may
improve patients’ quality of life.
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